SCHEMBL939306

SCHEMBL939306

Cc1cccc(Cl)c1S(=O)(=O)N(C)Cc1nc2cccc(C(=O)N3CCC4(CC3)CCN(c3ccncc3)CC4)c2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 9/20 0.40
CYP2D6 P10635 10/20 0.39
CYP1A2 P05177 7/20 0.39
SMN1; SMN2 Q16637 6/20 0.39
BDKRB1 P46663 1/20 0.39
CYP2C9 P11712 9/20 0.39
TSHR P16473 7/20 0.39
CYP2C19 P33261 6/20 0.39
HIF1A Q16665 5/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 1/20 0.38
USP2 O75604 2/20 0.37
MAPK1 P28482 2/20 0.35
ITGB3 P05106 2/20 0.35
ITGA2B P08514 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL938894 0.96 ITGB3 (0.39) CYP3A4CYP2D6CYP1A2SMN1; SMN2CYP2C9
SCHEMBL938222 0.93 CYP3A4 (0.39) CYP3A4CYP2D6CYP1A2SMN1; SMN2BDKRB1
SCHEMBL940776 0.89 CYP2D6 (0.47) CYP3A4CYP2D6CYP1A2SMN1; SMN2CYP2C9
SCHEMBL939921 0.89 CYP2C9 (0.40) CYP3A4CYP2D6CYP1A2SMN1; SMN2BDKRB1
SCHEMBL939220 0.86 CYP3A4 (0.45) CYP3A4CYP2D6CYP1A2SMN1; SMN2BDKRB1
SCHEMBL11947923 0.85 CYP3A4 (0.40) CYP3A4CYP2D6CYP1A2SMN1; SMN2BDKRB1
SCHEMBL938443 0.85 CYP3A4 (0.42) CYP3A4CYP2D6CYP1A2SMN1; SMN2CYP2C9
SCHEMBL939152 0.85 CYP3A4 (0.45) CYP3A4CYP2D6CYP1A2CYP2C9TSHR
SCHEMBL939902 0.84 ITGB3 (0.39) CYP3A4CYP2D6CYP1A2SMN1; SMN2CYP2C9
SCHEMBL939340 0.84 CYP2C9 (0.45) CYP3A4CYP2D6CYP1A2SMN1; SMN2BDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440542-B1 Substituted benzimidazoles, benzonthiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2013-12-18 EP claimed
US-8232288-B2 Substituted benzimidazoles, benzothiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2012-07-31 US claimed
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles GRUENENTHAL GMBH (DE) 2011-01-13 US claimed
WO-2010142402-A1 SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES Grünenthal GmbH (DE) 2010-12-16 WO claimed
EP-2440542-B1 Substituted benzimidazoles, benzonthiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2013-12-18 EP disclosed
US-8232288-B2 Substituted benzimidazoles, benzothiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2012-07-31 US disclosed
EP-2440542-A1 SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES Grünenthal GmbH (DE) 2012-04-18 EP disclosed
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles GRUENENTHAL GMBH (DE) 2011-01-13 US disclosed
WO-2010142402-A1 SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES Grünenthal GmbH (DE) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles BDKRB1, BDKRB2, BRD1 CYP3A4 253/4885CYP2D6 1223/4885CYP1A2 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.